Please use this identifier to cite or link to this item: https://doi.org/10.1007/s00213-015-4131-7
Title: Altered relaxin family receptors RXFP1 and RXFP3 in the neocortex of depressed Alzheimer's disease patients
Authors: Lee, Jasinda H 
Koh, Shu Qing
Guadagna, Simone
Francis, Paul T
Esiri, Margaret M
Chen, Christopher P 
Wong, Peter T-H 
Dawe, Gavin S 
Lai, Mitchell KP 
Keywords: Science & Technology
Life Sciences & Biomedicine
Neurosciences
Pharmacology & Pharmacy
Psychiatry
Neurosciences & Neurology
Alzheimer's disease
Dementia
Depression
Relaxin family peptides
RXFP1 receptors
RXFP3 receptors
NURSING-HOME PLACEMENT
CENTRAL-NERVOUS-SYSTEM
PSYCHIATRIC-SYMPTOMS
BEHAVIOR CHANGES
DEMENTIA
CORTEX
RAT
ACTIVATION
NEURONS
BINDING
Issue Date: 1-Feb-2016
Publisher: SPRINGER
Citation: Lee, Jasinda H, Koh, Shu Qing, Guadagna, Simone, Francis, Paul T, Esiri, Margaret M, Chen, Christopher P, Wong, Peter T-H, Dawe, Gavin S, Lai, Mitchell KP (2016-02-01). Altered relaxin family receptors RXFP1 and RXFP3 in the neocortex of depressed Alzheimer's disease patients. PSYCHOPHARMACOLOGY 233 (4) : 591-598. ScholarBank@NUS Repository. https://doi.org/10.1007/s00213-015-4131-7
Abstract: © 2015 Springer-Verlag Berlin Heidelberg. Rationale: The G-protein-coupled relaxin family receptors RXFP1 and RXFP3 are widely expressed in the cortex and are involved in stress responses and memory and emotional processing. However, the identification of these receptors in human cortex and their status in Alzheimer's disease (AD), which is characterized by both cognitive impairments and neuropsychiatric behaviours, have not been reported. Objectives: In this study, we characterized RXFP receptors for immunoblotting and measured RXFP1 and RXFP3 immunoreactivities in the postmortem neocortex of AD patients longitudinally assessed for depressive symptoms. Methods: RXFP1 and RXFP3 antibodies were characterized by immunoblotting with lysates from transfected HEK cells and preadsorption with RXFP3 peptides. Also, postmortem neocortical tissues from behaviourally assessed AD and age-matched controls were processed for immunoblotting with RXFP1 and RXFP3 antibodies. Results: Compared to controls, putative RXFP1 immunoreactivity was reduced in parietal cortex of non-depressed AD patients but unchanged in depressed patients. Furthermore, putative RXFP3 immunoreactivity was increased only in depressed AD patients. RXFP1 levels in the parietal cortex also correlated with severity of depression symptoms. In contrast, RXFP1 and RXFP3 levels did not correlate with dementia severity or β-amyloid burden. Conclusion: Alterations of RXFP1 and RXFP3 may be neurochemical markers of depression in AD, and relaxin family receptors warrant further preclinical investigations as possible therapeutic targets for neuropsychiatric symptoms in dementia.
Source Title: PSYCHOPHARMACOLOGY
URI: https://scholarbank.nus.edu.sg/handle/10635/188485
ISSN: 00333158
14322072
DOI: 10.1007/s00213-015-4131-7
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
43 Jas RXFP AD PSYCH 2016.pdf776.67 kBAdobe PDF

CLOSED

None

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.